快速尿液检测联合PSA与锌提升前列腺癌诊断:前瞻性研究
该前瞻性研究纳入260例拟行前列腺穿刺男性,开发结合尿PSA与尿锌的快速尿液检测。在242例可评估患者中,该检测单独AUC为0.769,联合标准诊疗参数后AUC升至0.789,联合mpMRI可达0.875。决策算法显示51%男性可安全避免穿刺,该组仅检出13%低级别前列腺癌。
要点
- 尿PSA与尿锌快速检测联合SOC参数可提升前列腺癌诊断准确性。
- 该尿液检测联合mpMRI的AUC达0.875,优于单独检测。
- 决策算法显示51%男性可安全避免穿刺,仅13%检出低级别癌。
核心结论
- uPSA/uZinc快速尿液检测是当前诊断路径的有前景辅助工具,可提高临床显著前列腺癌检出准确性并减少不必要穿刺。
- 该检测与mpMRI及SOC参数整合可优化风险评估和个体化管理。
研究设计与样本
- 前瞻性研究纳入260例接受前列腺穿刺的男性,采集按摩后尿液样本。
- 使用快速尿液检测结合侧流免疫分析(uPSA)与比色试纸法(uZinc),并以ELISA和比色体外试验确认。
- 构建Logistic回归模型(SOC、uPSA、uZinc、尿液检测、SOC+尿液检测)及mpMRI模型,以ROC分析的AUC评估诊断准确性。
主要发现
- 242例可评估患者中146例(59%)患有前列腺癌。
- 快速尿液检测强度评分与生物标志物浓度成反比;uPSA与临床分期、D'Amico风险及Gleason评分强相关,uZinc趋势较弱。
- 尿液检测AUC为0.769,SOC+尿液检测提升至0.789(p=0.0002)。
- 联合mpMRI的AUC分别为0.868(mpMRI+尿液检测)和0.875(mpMRI+SOC+尿液检测;p<0.0001)。
- 整合尿液检测的决策算法显示51%男性可安全避免穿刺,该组仅检出13%低级别前列腺癌(ISUP<2)。
关键数值与推荐
- 决策算法针对PSA升高至10 ng/mL、DRE阴性且PIRADS≤3的患者。
- 尿液检测联合SOC的AUC为0.789(p=0.0002),联合mpMRI的AUC为0.875(p<0.0001)。
临床怎么用
- 对于PSA升高至10 ng/mL、DRE阴性且PIRADS≤3的患者,可考虑采用uPSA/uZinc尿液检测辅助决策以减少不必要穿刺。
- 将尿液检测与mpMRI及SOC参数整合可优化风险分层和个体化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The need for simple, non-invasive biomarkers for prostate cancer (PCa) diagnosis is increasing. Urinary PSA (uPSA) and Zinc (uZinc) are emerging as potential PCa risk indicators. This study aimed to develop a rapid urine test combining uPSA and uZinc, assessing its diagnostic value alone and with Standard of Care (SOC) parameters, including age, serum PSA, DRE, and multiparametric Magnetic Resonance Imaging (mpMRI). METHODS: We enrolled 260 men undergoing prostate biopsy. Post-massage urine samples were analyzed using a rapid urine test combining lateral flow immunoassay (uPSA) and colorimetric dipstick assay (uZinc) with confirmatory testing via ELISA and colorimetric in vitro assay. Logistic regression models (SOC, uPSA, uZinc, Urine test [uPSA + uZinc], SOC + Urine test) and mpMRI models were tested. Diagnostic accuracy was evaluated using AUCs from ROC analysis. A decision-making algorithm targeting patients with increased PSA up to 10 ng/mL, negative DRE, and PIRADS ≤ 3 was proposed to assess the number of unnecessary biopsies potentially avoided with the urine test. RESULTS: Among 242 evaluable patients, 146 (59%) had PCa. The rapid Urine test provided intensity scores inversely proportional to biomarker concentration. uPSA strongly correlated with clinical stage, D'Amico risk, and Gleason score, while uZinc showed a weaker trend. The Urine test reached an AUC of 0.769, which improved performance to 0.789 with SOC + Urine test (p = 0.0002). Combining urine markers with mpMRI yielded AUCs of 0.868 (mpMRI+Urine test) and 0.875 (mpMRI+SOC+Urine test; p < 0.0001). The decision-making algorithm integrating urine test demonstrated that 51% of men could safely avoid biopsy, with a 13% detection rate of only low-grade PCas (ISUP < 2) in this group. CONCLUSIONS: This uPSA/uZinc urine test is a promising adjunct to current diagnostic pathways, improving accuracy in detecting clinically significant PCa while reducing unnecessary biopsies. Its integration with mpMRI and SOC parameters could refine risk assessment and personalize patient management.
引用
- Amparore D, De Cillis S, Zamengo D, et al. A rapid urinary test for combining PSA and zinc to enhance prostate cancer diagnosis: results from a prospective study. Prostate Cancer Prostatic Dis. 2025. PMID: 41354696. doi:10.1038/s41391-025-01030-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。